What is Portage Biotech Inc's earnings per share (EPS)?

Portage Biotech Inc (PRTG) reported diluted earnings per share of $0.46 for fiscal year 2018. This represents a 666.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Portage Biotech Inc Financials

PRTG

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2018 Currency USD FYE March

This page shows Portage Biotech Inc (PRTG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

-0.01x

For every $1 of reported earnings, Portage Biotech Inc generates $-0.01 in operating cash flow (-$1.1M OCF vs $123.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

$123.7M

YoY+659.2%

Portage Biotech Inc reported $123.7M in net income in fiscal year 2018. This represents an increase of 659.2% from the prior year.

EPS (Diluted)

$0.46

YoY+666.7%

Portage Biotech Inc earned $0.46 per diluted share (EPS) in fiscal year 2018. This represents an increase of 666.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$7.5M

YoY+4629.6%

Portage Biotech Inc held $7.5M in cash against $0 in long-term debt as of fiscal year 2018.

Dividends Per Share

N/A

Shares Outstanding

281M

YoY+7.7%

Portage Biotech Inc had 281M shares outstanding in fiscal year 2018. This represents an increase of 7.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

1286.4%

YoY+1259.1pp

Portage Biotech Inc's ROE was 1286.4% in fiscal year 2018, measuring profit generated per dollar of shareholder equity. This is up 1259.1 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

PRTG Income Statement

Metric	FY18	FY17	FY16
Revenue	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A
Net Income	$123.7M+659.2%	$16.3M+385.6%	-$5.7M
EPS (Diluted)	$0.46+666.7%	$0.06+400.0%	$-0.02

Metric	Q4'18	Q4'17
Revenue	N/A	N/A
Cost of Revenue	N/A	N/A
Gross Profit	N/A	N/A
R&D Expenses	N/A	N/A
SG&A Expenses	N/A	N/A
Operating Income	N/A	N/A
Interest Expense	N/A	N/A
Income Tax	N/A	N/A
Net Income	N/A	N/A
EPS (Diluted)	N/A	N/A

PRTG Balance Sheet

Metric	FY18	FY17	FY16
Total Assets	N/A	N/A	N/A
Current Assets	$7.6M-87.1%	$59.1M	N/A
Cash & Equivalents	$7.5M+4629.6%	$159K-96.6%	$4.7M
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	N/A	N/A	N/A
Current Liabilities	$127K+16.5%	$109K	N/A
Long-Term Debt	N/A	N/A	N/A
Total Equity	$9.6M-83.9%	$59.6M+383.4%	$12.3M
Retained Earnings	-$14.3M-195.7%	$15.0M	N/A

Metric	Q4'18	Q4'17
Total Assets	N/A	N/A
Current Assets	$7.6M-87.1%	$59.1M
Cash & Equivalents	$7.5M+4629.6%	$159K
Inventory	N/A	N/A
Accounts Receivable	N/A	N/A
Goodwill	N/A	N/A
Total Liabilities	N/A	N/A
Current Liabilities	$127K+16.5%	$109K
Long-Term Debt	N/A	N/A
Total Equity	$9.6M-83.9%	$59.6M
Retained Earnings	-$14.3M-195.7%	$15.0M

PRTG Cash Flow Statement

Metric	FY18	FY17	FY16
Operating Cash Flow	-$1.1M+18.8%	-$1.3M+77.4%	-$5.8M
Capital Expenditures	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A
Investing Cash Flow	$5.7M+266.0%	-$3.4M-100.5%	-$1.7M
Financing Cash Flow	$2.8M+1288.0%	$200K-98.1%	$10.5M
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q4'18	Q4'17
Operating Cash Flow	N/A	N/A
Capital Expenditures	N/A	N/A
Free Cash Flow	N/A	N/A
Investing Cash Flow	N/A	N/A
Financing Cash Flow	N/A	N/A
Dividends Paid	N/A	N/A
Share Buybacks	N/A	N/A

PRTG Financial Ratios

Metric	FY18	FY17	FY16
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A
Return on Equity	1286.4%+1259.1pp	27.4%+73.6pp	-46.3%
Return on Assets	N/A	N/A	N/A
Current Ratio	59.97-482.6	542.53	N/A
Debt-to-Equity	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A

Metric	Q4'18	Q4'17
Gross Margin	N/A	N/A
Operating Margin	N/A	N/A
Net Margin	N/A	N/A
Return on Equity	N/A	N/A
Return on Assets	N/A	N/A
Current Ratio	59.97-482.6	542.53
Debt-to-Equity	N/A	N/A
FCF Margin	N/A	N/A

Similar Companies

MetaVia Inc MTVA

$6.1M

Nextcure NXTC

$38.0M

Briacell Therapeutics Corp BCTX

$30.4M

Novabay Pharma NBY

$39.7M

Biolinerx BLRX

$10.0M

Frequently Asked Questions

Is Portage Biotech Inc profitable?

Yes, Portage Biotech Inc (PRTG) reported a net income of $123.7M in fiscal year 2018.

What is Portage Biotech Inc's return on equity (ROE)?

Portage Biotech Inc (PRTG) has a return on equity of 1286.4% for fiscal year 2018, measuring how efficiently the company generates profit from shareholder equity.

What is Portage Biotech Inc's operating cash flow?

Portage Biotech Inc (PRTG) generated -$1.1M in operating cash flow during fiscal year 2018, representing cash generated from core business activities.

How many shares does Portage Biotech Inc have outstanding?

Portage Biotech Inc (PRTG) had 281M shares outstanding as of fiscal year 2018.

What is Portage Biotech Inc's current ratio?

Portage Biotech Inc (PRTG) had a current ratio of 59.97 as of fiscal year 2018, which is generally considered healthy.

What is Portage Biotech Inc's cash runway?

Based on fiscal year 2018 data, Portage Biotech Inc (PRTG) had $7.5M in cash against an annual operating cash burn of $1.1M. This gives an estimated cash runway of approximately 84 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Are Portage Biotech Inc's earnings high quality?

Portage Biotech Inc (PRTG) has an earnings quality ratio of -0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.